BMRN
Biomarin Pharmaceutical Inc
61.40$
-1.4%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 22.0% | 21.0% | 19.3% | 18.3% | 25.3% | 18.2% | 20.3% | 18.2% | 18.0% | 33.7% | 25.4% | 20.5% | 24.5% | |
| 78.0% | 79.0% | 80.7% | 81.7% | 74.7% | 81.8% | 79.7% | 81.8% | 82.0% | 66.3% | 74.6% | 79.5% | 75.5% | |
| 32.9% | 31.9% | 31.6% | 25.8% | 24.8% | 23.2% | 21.3% | 19.5% | 52.8% | 22.0% | 23.3% | 20.9% | 29.0% | |
| 8.7% | 21.9% | 16.4% | 19.7% | 19.4% | 18.9% | 13.9% | 13.4% | 17.7% | 91.7% | 17.4% | 25.6% | 38.9% | |
| 72.7% | 76.8% | 67.1% | 64.8% | 59.5% | 60.2% | 49.6% | 48.3% | 88.0% | 57.2% | 57.6% | 68.3% | 67.5% | |
| 5.3% | 2.2% | 13.6% | 16.9% | 15.3% | 21.6% | 30.0% | 33.5% | -6.0% | 9.1% | 16.9% | 11.2% | 8.0% | |
| 0.7% | 0.9% | 0.5% | 0.5% | 0.4% | 0.3% | 0.4% | 0.3% | 0.3% | 0.3% | 2.0% | 6.4% | 2.5% | |
| 7.2% | 3.0% | 16.3% | 18.6% | 18.0% | 22.7% | 32.0% | 36.1% | -3.4% | -3.1% | 18.4% | 6.2% | 4.4% | |
| 0.2% | -0.2% | 2.6% | 3.5% | 3.8% | 6.0% | 7.0% | 6.9% | 0.6% | 2.2% | 4.7% | 1.7% | 2.2% | |
| 6.9% | 3.2% | 13.7% | 15.1% | 14.2% | 16.7% | 24.9% | 29.1% | -4.0% | -5.3% | 13.8% | 4.5% | 2.1% | |
| 12.2% | 8.0% | 21.0% | 22.8% | 21.0% | 26.2% | 35.3% | 38.7% | -0.7% | -0.5% | 22.5% | 22.5% | 11.3% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.